USA: Actual FDA Approved Cannabis Based Drug at $32K

Spread the love

Cannabis-Based Drug is Priced at $32,500

GW Pharmaceuticals PLC said  it plans to charge about $32,500 per patient annually in the U. S.

for its new treatment for rare forms of epilepsy, the first prescription drug derived from the marijuana plant.

The U. S. Food and Drug Administration approved Epidiolex, also known as cannabidiol, in June to

reduce seizures associated with forms of epilepsy known as Lennox-Gastaut syndrome and Davet syndrome, in patients 2 years of age and older.

GW Pharmaceuticals, based in the UK, makes cannabidiol from a proprietary strain of cannabis designed to maximize a therapeutic component while minimizing components that produce euphoria or a high.

Chief Executive Justin Gover said in an interview Wednesday that the company set the price to be in line with other brand-name epilepsy drugs, such as Lundbeck AS’s Onfi.  He noted that the FDA designated the product as “orphan drug”, meaning it treats rare conditions, and that some other orphan drugs carry higher prices. . . .

Out of pocket costs for patients taking Epidiolex could range from $5 to $10 a month for those in state Medicaid programs to as high as $200 a month for some private insurance plans. . . . Uninsured patients may qualify for receiving the drug free.

Jacqueline French, chief scientific officer of the Epilepsy Foundation, said there are low-cost generic epilepsy drugs on the market, but many patients with rare forms of the disease have tried them and the drugs didn’t help much.

Dr. French said Epidiolex improved symptoms for many children in clinical trials, and she is happy the price isn’t significantly higher.

The company expects to make the drug available after the U. S. Drug Enforcement Agency assigns it a controlled substance classification, a decision expected by late September.  GW Pharmaceuticals will distribute the drug through specialty pharmacies that ship directly to patients and caregivers.

Wall Street Journal, Aug. 9, 2018 – Business & Finance



Leave a Reply